These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 23880170)

  • 1. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review.
    Parker S; Lipman J; Koulenti D; Dimopoulos G; Roberts JA
    Int J Antimicrob Agents; 2013 Oct; 42(4):289-93. PubMed ID: 23880170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deciphering pharmacokinetics and pharmacodynamics of fosfomycin.
    Rodríguez-Gascón A; Canut-Blasco A
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):19-24. PubMed ID: 31131588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections.
    Roussos N; Karageorgopoulos DE; Samonis G; Falagas ME
    Int J Antimicrob Agents; 2009 Dec; 34(6):506-15. PubMed ID: 19828298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies.
    Antonello RM; Di Bella S; Maraolo AE; Luzzati R
    Eur J Clin Microbiol Infect Dis; 2021 Jun; 40(6):1117-1126. PubMed ID: 33604721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous fosfomycin for the treatment of hospitalized patients with serious infections.
    Shorr AF; Pogue JM; Mohr JF
    Expert Rev Anti Infect Ther; 2017 Oct; 15(10):935-945. PubMed ID: 28901793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetics of Fosfomycin in Critically Ill Patients.
    Parker SL; Frantzeskaki F; Wallis SC; Diakaki C; Giamarellou H; Koulenti D; Karaiskos I; Lipman J; Dimopoulos G; Roberts JA
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6471-6. PubMed ID: 26239990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?
    Jamal JA; Mueller BA; Choi GY; Lipman J; Roberts JA
    Diagn Microbiol Infect Dis; 2015 May; 82(1):92-103. PubMed ID: 25698632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation.
    Asuphon O; Montakantikul P; Houngsaitong J; Kiratisin P; Sonthisombat P
    Int J Infect Dis; 2016 Sep; 50():23-9. PubMed ID: 27418581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fosfomycin--its significance for treatment of diseases due to multidrug-resistant bacteria].
    Stock I
    Med Monatsschr Pharm; 2015 Jan; 38(1):4-11. PubMed ID: 26349119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation.
    Michalopoulos A; Virtzili S; Rafailidis P; Chalevelakis G; Damala M; Falagas ME
    Clin Microbiol Infect; 2010 Feb; 16(2):184-6. PubMed ID: 19694767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current clinical use of intravenous fosfomycin in ICU patients in two European countries.
    Putensen C; Ellger B; Sakka SG; Weyland A; Schmidt K; Zoller M; Weiler N; Kindgen-Milles D; Jaschinski U; Weile J; Lindau S; Kieninger M; Faltlhauser A; Jung N; Teschendorf P; Adamzik M; Gründling M; Wahlers T; Gerlach H; Litty FA
    Infection; 2019 Oct; 47(5):827-836. PubMed ID: 31190298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli.
    Merino-Bohórquez V; Docobo-Pérez F; Sojo J; Morales I; Lupión C; Martín D; Cameán M; Hope W; Pascual Á; Rodríguez-Baño J
    Clin Microbiol Infect; 2018 Nov; 24(11):1177-1183. PubMed ID: 29649596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A reappraisal of current dosing strategies for intravenous fosfomycin in children and neonates.
    Traunmüller F; Popovic M; Konz KH; Vavken P; Leithner A; Joukhadar C
    Clin Pharmacokinet; 2011 Aug; 50(8):493-503. PubMed ID: 21740073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous fosfomycin for the treatment of patients with central nervous system infections: evaluation of the published evidence.
    Tsegka KG; Voulgaris GL; Kyriakidou M; Falagas ME
    Expert Rev Anti Infect Ther; 2020 Jul; 18(7):657-668. PubMed ID: 32397774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
    Pontikis K; Karaiskos I; Bastani S; Dimopoulos G; Kalogirou M; Katsiari M; Oikonomou A; Poulakou G; Roilides E; Giamarellou H
    Int J Antimicrob Agents; 2014 Jan; 43(1):52-9. PubMed ID: 24183799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using PK/PD to optimize antibiotic dosing for critically ill patients.
    Roberts JA
    Curr Pharm Biotechnol; 2011 Dec; 12(12):2070-9. PubMed ID: 21554211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens?
    Dimopoulos G; Koulenti D; Parker SL; Roberts JA; Arvaniti K; Poulakou G
    Expert Rev Anti Infect Ther; 2019 Mar; 17(3):201-210. PubMed ID: 30668931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.
    Li G; Standing JF; Bielicki J; Hope W; van den Anker J; Heath PT; Sharland M
    Drugs; 2017 Jun; 77(9):941-950. PubMed ID: 28456943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of continuous renal replacement therapy on antibiotic pharmacokinetics in critically ill patients.
    Fiore M; Peluso L; Taccone FS; Hites M
    Expert Opin Drug Metab Toxicol; 2021 May; 17(5):543-554. PubMed ID: 33733979
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients.
    Heavner MS; Claeys KC; Masich AM; Gonzales JP
    Curr Infect Dis Rep; 2018 Apr; 20(5):10. PubMed ID: 29623443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.